Small Animal Imaging Market By Imaging Modality (X-ray Imaging, Ultrasound Imaging, Computed Tomography, MRI, Nuclear Imaging, Other Modalities); By Animal Type (Dogs, Cats, Other Small Animals); By Application (Orthopedic and Musculoskeletal Imaging, Oncology Imaging, Cardiac Imaging, Neurological Imaging, Abdominal and Gastrointestinal Imaging, Other Applications); By End User (Veterinary Hospitals and Specialty Clinics, Veterinary Clinics, Research Institutes and Universities, Other End Users); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Small Animal Imaging Market: Veterinary Diagnostics, Preclinical Research and Translational Imaging

The Global Small Animal Imaging Market was valued at USD 1.37 billion in 2025 and is projected to reach USD 2.27 billion by 2032, expanding at a CAGR of 7.48% during 2026–2032, according to Strategic Market Research.

 

Small animal imaging supports the non-invasive assessment of anatomy, physiology, metabolism, molecular activity, and treatment response in living animals. Within this market, two connected but operationally different areas generate demand: clinical veterinary imaging of companion animals, particularly dogs and cats, and in-vivo preclinical imaging of mice, rats, and other laboratory research models.

 

The longitudinal capability of imaging is particularly important in preclinical research. MRI, micro-CT, PET/SPECT, optical imaging, and high-frequency ultrasound allow investigators to study the same animal repeatedly over several time points. This reduces inter-animal variability, provides a clearer view of disease progression and therapeutic response, and can reduce the number of animals required compared with experimental designs that depend on separate cohorts at every observation point.

 

The market consequently relies on complementary modalities rather than one universally superior technology. MRI provides high soft-tissue contrast for neurological, cardiac, musculoskeletal, and anatomical research. Micro-CT delivers high-resolution structural information for bone, lung, dental, and calcified tissues. PET and SPECT measure metabolic activity, receptor behavior, biodistribution, and other molecular processes through radiotracers. Optical imaging, including bioluminescence and fluorescence, allows relatively rapid and cost-effective tracking of tumors, engineered cells, and gene expression. High-frequency ultrasound provides real-time cardiovascular, vascular, and soft-tissue information without ionizing radiation. Photoacoustic and other specialized modalities extend the market into more focused molecular and functional research applications.

 

In veterinary medicine, the technology mix is different. Digital radiography and ultrasound dominate routine diagnostic work because they are accessible to a broad range of practices, while CT and MRI are concentrated in referral hospitals, specialty clinics, veterinary teaching facilities, and high-complexity cases.

 

Small Animal Imaging Market Snapshot Across Modalities, Animal Types, and Clinical-Research Applications

Routine Radiography Leads While MRI Accelerates the Imaging Modality Mix

• X-ray imaging led the market with approximately 31% share and USD 424.7 million in 2025. It is projected to expand at a 6.2% CAGR through 2032. Its leadership reflects the continued importance of radiography for fractures, joint disorders, thoracic disease, abdominal assessment, and routine musculoskeletal diagnosis.

• Ultrasound imaging represented approximately 27% share and USD 369.9 million, with a projected 7.3% CAGR. It is widely used for abdominal, reproductive, cardiac, vascular, and soft-tissue examinations and also plays an important role in research through ultra-high-frequency systems capable of resolving small-animal cardiovascular and tumor structures.

• Computed tomography accounted for 18% share and USD 246.6 million, with an estimated 8.5% CAGR. Growth is being supported by oncology staging, trauma, complex orthopedic evaluation, pulmonary imaging, and surgical planning. Micro-CT provides a parallel research opportunity by enabling highly detailed imaging of small skeletal, pulmonary, and anatomical structures.

• MRI held approximately 14% share and USD 191.8 million in 2025 and is the fastest-growing major modality, with a projected 9.0% CAGR. Veterinary growth comes from neurological, spinal, musculoskeletal, and advanced soft-tissue cases, while preclinical MRI supports longitudinal brain, cardiac, tumor, developmental, and functional studies.

• Nuclear imaging accounted for approximately 4% share and USD 54.8 million, expanding at around 8.0% CAGR. PET and SPECT remain concentrated in research, academic, and specialist centers where molecular and functional information is required.

• Other modalities accounted for approximately 6% share and USD 82.2 million, including optical imaging, photoacoustic imaging, fluoroscopy, and other specialized technologies.

 

Canine Imaging Sustains Animal-Type Revenue While Research Rodents Add Strategic Demand

• Dogs accounted for approximately 62% of market revenue, equivalent to USD 849.4 million in 2025, and are projected to grow at 7.6% CAGR. Their dominant position reflects substantial imaging use across orthopedic injuries, degenerative joint disease, oncology, cardiovascular disease, trauma, and neurological disorders. Dogs are also frequently referred for CT and MRI, increasing their exposure to higher-value imaging procedures.

• Cats represented approximately 30% share and USD 411.0 million, with a projected 7.3% CAGR. Increasing use of ultrasound, digital radiography, CT, and MRI is supporting more advanced diagnosis of feline abdominal, cardiac, neurological, oncological, and musculoskeletal conditions.

• Other small animals represented approximately 8% share and USD 109.6 million, growing at around 7.1% CAGR. This category includes rabbits, birds, reptiles, rodents, and other specialist companion species. Rodents also represent a separate and strategically important research population in preclinical imaging laboratories.

 

Orthopedic Volume and Oncology Growth Anchor Clinical and Research Applications

Demand extends across oncology, cardiology, neurology, orthopedic imaging, drug discovery, phenotyping, pharmacology, and longitudinal disease-model research.

• Orthopedic and musculoskeletal imaging remains the largest application, accounting for approximately 30% share and USD 411.0 million in 2025. Radiography is fundamental to fracture, arthritis, spinal, and joint assessment, while CT and MRI are used when greater structural or soft-tissue detail is required.

• Oncology imaging, with approximately 23% share and USD 315.1 million, is the fastest-growing major application at an estimated 8.8% CAGR. In veterinary care, imaging is used for tumor localization, staging, biopsy guidance, surgical planning, therapy selection, and follow-up. In preclinical research, investigators can repeatedly measure tumor volume, metastasis, metabolic activity, vascular changes, and response to investigational anticancer therapies.

• Cardiac imaging represented around 15% share and USD 205.5 million, supported by echocardiography, MRI, and selected PET applications for myocardial blood flow, ventricular function, and tissue behavior.

• Neurological imaging accounted for approximately 12% share and USD 164.4 million and is expanding at approximately 8.6% CAGR. Research applications include neurodegenerative disease, receptor occupancy, cerebral blood flow, and disease-model characterization, while veterinary MRI supports diagnosis of brain and spinal conditions.

• Abdominal and gastrointestinal imaging represented about 13% share and USD 178.1 million, while other applications, including reproductive, respiratory, and ophthalmic imaging, accounted for approximately 7%.

 

Longitudinal Imaging Strengthens Drug Discovery and Translational Research

Preclinical imaging adds value well before a product reaches human trials. Imaging can be used to characterize pharmacokinetics, pharmacodynamics, biodistribution, target engagement, toxicity, and early therapeutic efficacy without depending exclusively on terminal tissue analysis.

Phenotyping is another important application. Genetically engineered mouse and other disease models can be characterized structurally and functionally to determine how specific genetic changes influence anatomy, metabolism, cardiovascular function, tumor biology, or neurological disease.

Research activity provides a substantial underlying user base. Great Britain recorded approximately 2.54 million regulated scientific procedures in 2025, with mice, fish, birds, and rats representing about 95% of procedures. Germany reported around 1.46 million experimental animals in 2023, with rodents accounting for approximately 80%.

Not every animal procedure involves imaging, but the scale of experimental research explains why universities, cancer centers, pharmaceutical companies, and shared imaging facilities continue investing in specialized preclinical infrastructure.

 

Detector Sensitivity and Quantification Advance PET and SPECT Research Value

Preclinical PET and SPECT development is increasingly focused on detector performance, electronics, image reconstruction, sensitivity, and quantitative accuracy.

Small-animal molecular imaging places unusually demanding requirements on spatial resolution because structures and tumors are considerably smaller than their human equivalents. Improvements in detector architecture and reconstruction therefore have a direct effect on the biological questions that researchers can investigate.

Greater sensitivity can also reduce the activity of radiotracer required or shorten acquisition time, while improved quantitative performance strengthens pharmacokinetic, receptor-occupancy, and longitudinal treatment-response studies.

These advances matter commercially because PET and SPECT are becoming less valuable as purely visual imaging tools and more valuable as quantitative platforms for measuring biological change.

 

Multimodal Imaging Integrates Molecular Signals With Anatomical Precision

Multimodal systems such as PET/CT, PET/MRI, and SPECT/CT combine complementary information in one research workflow. PET or SPECT can identify metabolic or molecular activity, while CT or MRI provides the anatomical context needed to locate and quantify that signal accurately.

Integrated workflows also reduce the problems created by repeatedly repositioning a small animal between scanners. Transferable or shared heated imaging beds, anesthesia support, animal isolation systems, and physiological monitoring are becoming increasingly important because body temperature, posture, anesthesia duration, breathing, and cardiac activity can influence experimental results.

Maintaining a similar physiological state across multiple acquisitions improves image registration and makes longitudinal datasets more reproducible.

The market is therefore advancing not only through better scanners, but through better control of the complete imaging experiment.

 

AI Reconstruction and Quantitative Analysis Shift Value Toward Imaging Software

AI-enabled reconstruction and post-processing are being developed to reduce image noise, shorten acquisition times, improve segmentation, quantify imaging biomarkers, and increase reproducibility.

Shorter scans are particularly valuable in small-animal studies because they can reduce anesthesia exposure and allow a research facility to image more animals within the same scanner schedule. In veterinary settings, faster acquisition can also improve throughput and reduce the time required for sedated or anesthetized examinations.

AI creates a second opportunity after acquisition. Automated measurements, lesion segmentation, cardiac quantification, longitudinal comparison, workflow prioritization, and multimodality image analysis can increase the amount of clinically or scientifically useful information generated from existing scanners.

This shifts part of future market value from hardware toward software, analytics, and recurring imaging services.

 

Workflow Efficiency and Physiological Support Reshape Advanced CT and MRI

Newer CT and MRI systems are increasingly designed around faster acquisition, more flexible animal positioning, wider usable bore configurations, improved reconstruction, and easier integration with physiological support equipment.

The objective is no longer simply to increase theoretical spatial resolution. Research facilities increasingly evaluate how quickly animals can be prepared, scanned, recovered, transferred between modalities, and processed analytically.

This is especially important for shared imaging facilities, where scanner economics depend heavily on utilization and the number of studies completed per day.

 

Magnetic Particle Imaging Opens a Specialized Tracer-Based Research Segment

Magnetic Particle Imaging (MPI) represents an emerging but still specialized area of small-animal imaging. MPI directly detects magnetic nanoparticle tracers and can provide background-free, highly sensitive, real-time three-dimensional information.

Potential applications include cell tracking, vascular imaging, perfusion research, nanoparticle-tracer development, and longitudinal monitoring.

Its commercial installed base remains considerably smaller than MRI, CT, PET, ultrasound, or optical imaging. However, the absence of conventional tissue background gives MPI a distinctive research advantage in applications where detecting relatively small concentrations of tracer is more important than obtaining conventional anatomical contrast.

 

Translational Radiotracers and Molecular Probes Extend Imaging Beyond Equipment

The development of radiotracers and molecular imaging probes is becoming increasingly important because a successful imaging agent can connect preclinical experiments directly with clinical research.

Small-animal PET and SPECT can establish biodistribution, target specificity, pharmacokinetics, dosimetry, and receptor engagement before a tracer progresses into human studies. Examples include next-generation PET agents for neurodegenerative disorders and oncology targets such as PSMA.

This creates commercial value beyond equipment sales. Tracer development, radiochemistry, quantitative software, imaging protocols, and companion biomarker strategies can become part of the broader imaging ecosystem.

A preclinical imaging endpoint becomes significantly more valuable when the same biological measurement can later be reproduced in a Phase 0, Phase I, or subsequent clinical trial.

 

Specialized Preclinical Platforms Compete Through Modality Depth and Research Integration

The research market contains several highly specialized technology platforms.

Revvity/Caliper IVIS systems are widely used for bioluminescence and fluorescence imaging, particularly in oncology, cell tracking, infectious disease, and longitudinal molecular studies.

Bruker SkyScan systems provide micro-CT capability for high-resolution structural imaging, while Bruker's broader research portfolio also includes MRI and molecular-imaging technologies.

FUJIFILM VisualSonics Vevo platforms provide ultra-high-frequency ultrasound for cardiovascular, oncology, vascular, developmental, and image-guided research.

MOLECUBES offers modular PET, CT, and SPECT systems designed for flexible small-animal molecular-imaging configurations.

Higher-end systems such as United Imaging's uBioEXPLORER and Sedecal's Super Argus PET/CT illustrate continuing investment in detector sensitivity, quantitative molecular imaging, and integrated animal-management workflows.

These platforms serve a different commercial market from routine veterinary radiography. Their purchasing decisions are more strongly influenced by research protocols, multimodality compatibility, quantitative accuracy, tracer capability, and integration with shared research facilities.

 

Veterinary Referral Care and Research Facilities Shape End-User Adoption

Veterinary hospitals and specialty clinics held approximately 48% market share and USD 657.6 million in 2025, expanding at around 7.9% CAGR. Their leadership reflects the concentration of complex oncology, neurological, orthopedic, cardiovascular, and emergency cases requiring CT, MRI, advanced ultrasound, and specialist interpretation.

General veterinary clinics represented approximately 31% share and USD 424.7 million, growing at around 6.8% CAGR. These facilities remain an important volume market for digital radiography and ultrasound.

Research institutes and universities accounted for approximately 14% share and USD 191.8 million and represent the fastest-growing end-user segment at approximately 8.0% CAGR. Demand comes from comparative oncology, drug development, molecular imaging, veterinary teaching hospitals, phenotyping, and shared preclinical imaging facilities.

Other end users accounted for approximately 7% and include diagnostic imaging centers, specialized service providers, and related research organizations.

 

North American Scale and Asia Pacific Expansion Define Regional Growth

North America led the market with approximately 40% share and USD 548.0 million in 2025, supported by extensive companion-animal healthcare infrastructure, specialty veterinary hospitals, pharmaceutical research, academic medical centers, and established shared imaging facilities.

Europe represented approximately 29% share and USD 397.3 million, with a projected 7.0% CAGR. Veterinary referral networks, academic research infrastructure, pharmaceutical development, and animal-research governance shape regional demand.

Asia Pacific accounted for approximately 21% share and USD 287.7 million and is the fastest-growing region at an estimated 9.5% CAGR. Increasing companion-animal healthcare spending, specialty hospitals, university research programs, and wider availability of CT, MRI, and advanced ultrasound are expanding the regional addressable market.

Latin America represented approximately 6% share and USD 82.2 million, growing at around 7.7%, while the Middle East & Africa accounted for approximately 4% and USD 54.8 million, with advanced imaging concentrated in major veterinary hospitals, specialist centers, and universities.

 

Animal-Welfare Oversight and Translational Pathways Shape Research Investment

Dedicated small-animal imaging systems marketed exclusively for laboratory research generally operate under a different regulatory framework from human medical devices and do not automatically follow the same FDA 510(k) or PMA approval pathway.

Research use is nevertheless governed by institutional animal-welfare oversight, study protocols, radiation-safety requirements, and Good Laboratory Practice where applicable. The regulatory burden changes substantially when a scanner, software algorithm, molecular probe, or radiotracer begins moving from laboratory research into veterinary clinical practice or human development.

Initiatives intended to reduce and replace animal experimentation create an important market dynamic. Lower reliance on animal models can restrain some traditional preclinical activity, but longitudinal imaging directly supports the principle of reduction because the same subject can provide several time-point measurements.

Imaging systems capable of producing several anatomical, functional, and molecular endpoints from fewer animals may therefore become more valuable as pharmaceutical and academic researchers face stronger pressure to improve experimental efficiency.

 

Veterinary Workflow Providers and Preclinical Specialists Divide the Competitive Landscape

IDEXX Laboratories

IDEXX Laboratories has a strong position in high-volume veterinary diagnostic workflows. Its ImageVue DR30 and DR50 digital radiography systems address general and higher-throughput veterinary practices, while IDEXX Web PACS integrates radiography, ultrasound, CT, and MRI images with practice-management and specialist consultation workflows.

Its competitive advantage lies less in one scanner category than in connecting imaging equipment, image management, tele-radiology, and veterinary diagnostic workflows.

FUJIFILM

FUJIFILM is particularly well aligned with digital radiography, the market's largest imaging modality, while also maintaining veterinary ultrasound and image-management capabilities.

Its FVS-1000 and related veterinary workflows support acquisition, processing, reporting, and management across digital radiography and other imaging data, positioning the company around integrated clinical workflows rather than stand-alone equipment.

GE HealthCare

GE HealthCare maintains relevant exposure through portable and advanced ultrasound platforms used in veterinary applications, including cardiovascular and soft-tissue imaging. Its position is stronger within ultrasound than across the complete small-animal imaging market.

Esaote

Esaote is differentiated by dedicated veterinary MRI systems such as Vet-MR and Vet-MR Grande. Although MRI represents a smaller installed base than radiography or ultrasound, its higher growth rate and importance in neurology and complex musculoskeletal imaging create a premium specialty opportunity.

Siemens Healthineers

Siemens Healthineers participates in advanced veterinary imaging through MRI platforms used in referral and specialty environments. Its strongest opportunity lies in complex neurological, spinal, and advanced soft-tissue cases.

Mindray Animal Medical

Mindray Animal Medical is an important veterinary ultrasound participant through Vetus and other dedicated animal-imaging platforms, with strong relevance to cardiovascular, abdominal, and routine specialist ultrasound.

Bruker Corporation

Bruker is particularly important in preclinical research rather than routine veterinary diagnostics. Its portfolio spans micro-CT, MRI, PET/SPECT, and related molecular-imaging technologies, giving it broad exposure to multimodal research infrastructure.

Revvity

Revvity's IVIS platform maintains a significant position in fluorescence and bioluminescence research imaging. Its commercial relevance is particularly strong in longitudinal oncology, cell tracking, infectious disease, and molecular biology studies.

Mediso and MOLECUBES

Mediso addresses high-value preclinical PET/CT, SPECT/CT, and PET/MRI applications, while MOLECUBES provides modular nuclear and structural imaging configurations for small-animal research.

The competitive market therefore separates naturally into clinical veterinary workflow providers and research-focused preclinical imaging suppliers, with different purchasing criteria and revenue models.

 

Accessible Advanced Diagnostics and Translational Imaging Define the Next Market Whitespace

The largest future opportunities are likely to emerge in areas where existing imaging capability fails to match the needs of the user rather than from incremental increases in scanner resolution.

In veterinary medicine, the major gap remains between widely available radiography and ultrasound and referral-level CT/MRI. Compact CT or MRI systems, lower infrastructure requirements, mobile imaging services, shared-equipment models, and more flexible financing could bring advanced cross-sectional imaging into a much larger group of practices.

The second opportunity is in the software layer. AI-assisted measurements, cloud PACS, automated image comparison, tele-radiology, quantitative oncology tools, and multimodal case management can create recurring revenue from existing installed hardware while reducing dependence on scarce specialist interpretation.

Preclinical research presents a different commercial opportunity: generating more translational information from fewer animals. A platform that combines molecular and anatomical imaging, standardized animal handling, physiological monitoring, quantitative analysis, and longitudinal data can reduce experimental variability and potentially improve decisions about which therapeutic candidates should progress.

The most strategically valuable preclinical platforms will be those capable of producing biomarkers and imaging endpoints that survive the transition from animal studies into human development. This strengthens the case for PET tracers, multimodal PET/MRI or PET/CT workflows, quantitative MRI, advanced reconstruction, MPI, and standardized longitudinal analysis.

Over the longer term, competitive advantage is likely to depend on how effectively a company links image acquisition, quantitative interpretation, animal or patient workflow, longitudinal data, and translational decision-making. In veterinary care, that means making advanced imaging easier to access and interpret. In drug development, it means turning an animal scan into evidence that remains relevant when the therapeutic program enters human trials.

 

Small Animal Imaging Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 1.37 Billion
Revenue Forecast in 2032	USD 2.27 Billion
Overall Growth Rate	CAGR of 7.48% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Billion, CAGR (2026–2032)
Segmentation	By Imaging Modality, By Animal Type, By Application, By End User, By Geography
By Imaging Modality	X-ray Imaging, Ultrasound Imaging, Computed Tomography, MRI, Nuclear Imaging, Other Modalities
By Animal Type	Dogs, Cats, Other Small Animals
By Application	Orthopedic and Musculoskeletal Imaging, Oncology Imaging, Cardiac Imaging, Neurological Imaging, Abdominal and Gastrointestinal Imaging, Other Applications
By End User	Veterinary Hospitals and Specialty Clinics, Veterinary Clinics, Research Institutes and Universities, Other End Users
By Region	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Companion-animal healthcare infrastructure, specialty veterinary hospitals, pharmaceutical research, academic medical centers, shared imaging facilities, translational research, and wider availability of advanced imaging
Customization Option	Available upon request